Emcure Pharmaceuticals
MAINBOARD
Listed
Price Band
₹960 - ₹1,008
Lot Size
14 Shares
Issue Size
₹800.00 Cr
Fresh Issue
₹560.00 Cr
OFS
₹240.00 Cr
Registrar
Link Intime India Private Limited
AI Sentiment Score
Listing Price
₹1,325.05
vs Issue: ₹1,008 (+31.45%)
📅 IPO Timeline
✓
Open
Jul 3, 2024
✓
Close
Jul 5, 2024
✓
Allotment
Jul 8, 2024
✓
Refund
Jul 9, 2024
✓
Demat
Jul 9, 2024
✓
Listing
Jul 10, 2024
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
Emcure Pharmaceuticals displays an established operational footprint with expanding revenue streams (15.4% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (15.4% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 24.0%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 5,986.00 Cr | Rs 6,658.00 Cr | Rs 7,896.00 Cr | Rs 9,204.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 562.00 Cr | Rs 528.00 Cr | Rs 707.00 Cr | Rs 941.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 1,182.00 Cr | Rs 1,230.00 Cr | Rs 1,469.00 Cr | Rs 1,746.00 Cr |
| Borrowings (₹ Cr) | Rs 2,334.00 Cr | Rs 2,335.00 Cr | Rs 1,023.00 Cr | Rs 1,521.00 Cr |
| Total Assets (₹ Cr) | Rs 6,634.00 Cr | Rs 7,709.00 Cr | Rs 8,122.00 Cr | Rs 9,514.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 24.00% | 24.00% | 24.00% | 24.00% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
35.4x
Industry P/E
40.7x
Debt/Equity
0.31
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 40.7x
IPO 35.4x
0x (Deep Value)
55x (High Multiple)
📋 Live Subscription Status
QIB
195.83x
NII
53.79x
Retail
7.21x
Total
67.87x
🎯 Retail Allotment Probability
13.9% Odds
1 in 7.2 chance (~13.9% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:43 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹800.0 Cr
Issue Size
Fresh (70%)
OFS (30%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.